Extracellular Vesicle ASO Constructs Targeting STAT6
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering antisense oligonucleotides (ASOs) and PD-1 antagonists face challenges in stability and targeting efficiency, limiting their therapeutic potential in treating diseases such as cancer by modulating STAT6 expression and immune response.
Innovation Solution
Administering extracellular vesicles (EVs), specifically exosomes, engineered to carry ASOs with complementary nucleotide sequences and PD-1 antagonists, such as anti-PD-1 antibodies, to target and reduce STAT6 expression and enhance immune responses in cancer treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional drug delivery methods are used to deliver ASOs and PD-1 antagonists, then the therapeutic agents can reach target cells, but the stability and targeting efficiency are insufficient
Solution Approach 1:
The patent uses extracellular vesicles (EVs) as intermediary carriers to deliver ASOs and PD-1 antagonists. The EVs are engineered to incorporate targeting ligands on their surface that specifically bind to receptors on tumor-associated macrophages and other target cells, thereby improving both stability during circulation and targeting efficiency at the disease site without requiring complex manufacturing processes
Solution Approach 2:
The invention creates a composite delivery system where extracellular vesicles (natural biological structures) are combined with synthetic therapeutic agents (ASOs and PD-1 antagonists). This composite approach leverages the biocompatibility and stability of EVs while incorporating the potent gene-silencing and immune-modulating activities of the therapeutic molecules, achieving enhanced overall performance
2Reliability
If ASOs are administered to reduce STAT6 expression, then gene expression is regulated, but stability and targeting of ASOs in vivo remains insufficient
Solution Approach 1:
The patent employs extracellular vesicles as protective intermediaries that encapsulate ASOs, shielding them from nucleases and other degradation mechanisms in the bloodstream. The EV membrane provides a stable environment that maintains ASO integrity during circulation and delivery to target tissues, thereby significantly improving in vivo stability while maintaining effective gene expression regulation
Solution Approach 2:
The invention modifies the physical and chemical parameters of ASO delivery by incorporating them into extracellular vesicles. This changes the delivery vehicle from a simple molecular form to a protected vesicular form, altering parameters such as circulation half-life, biodistribution, and resistance to degradation, thereby improving overall stability and effectiveness
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively increases immune response and tumor targeting, converting 'cold' tumors into 'hot' tumors, inducing M1 polarization of macrophages, and promoting anti-tumor immunity, thereby enhancing cancer treatment efficacy.
Implementation Method 1
the ASO comprises a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within a STAT6 transcript
Data Source
AI summary
The present disclosure relates to extracellular vesicles, e.g., exosomes, comprising an antisense oligonucleotide (ASO), wherein the ASO comprises a contiguous nucleotide sequence of 10 to 30 nucleotides in length that is complementary to a nucleic acid sequence within a STAT6 transcript. Also provided herein are methods for producing the exosomes and methods for using the exosomes to treat and/or prevent diseases or disorders.